Literature DB >> 33555272

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

Filip Matthijssens1,2, Nitesh D Sharma3,4, Monique Nysus3,4, Christian K Nickl3,4, Huining Kang4,5, Dominique R Perez4,6, Beatrice Lintermans1,2, Wouter Van Loocke1,2, Juliette Roels1,2, Sofie Peirs1,2, Lisa Demoen1,2, Tim Pieters1,2, Lindy Reunes1,2, Tim Lammens2,7, Barbara De Moerloose2,7, Filip Van Nieuwerburgh8, Dieter L Deforce8, Laurence C Cheung9,10, Rishi S Kotecha9,10, Martijn Dp Risseeuw2,11, Serge Van Calenbergh2,11, Takeshi Takarada12, Yukio Yoneda13, Frederik W van Delft14, Richard B Lock15, Seth D Merkley5, Alexandre Chigaev4,6, Larry A Sklar4,6, Charles G Mullighan16, Mignon L Loh17, Stuart S Winter18, Stephen P Hunger19, Steven Goossens1,2,20, Eliseo F Castillo5, Wojciech Ornatowski21, Pieter Van Vlierberghe1,2, Ksenia Matlawska-Wasowska3,4.   

Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2) was upregulated in high-risk T-ALL with KMT2A rearrangements (KMT2A-R) or an immature immunophenotype. In KMT2A-R cells, we identified RUNX2 as a direct target of the KMT2A chimeras, where it reciprocally bound the KMT2A promoter, establishing a regulatory feed-forward mechanism. Notably, RUNX2 was required for survival of immature and KMT2A-R T-ALL cells in vitro and in vivo. We report direct transcriptional regulation of CXCR4 signaling by RUNX2, thereby promoting chemotaxis, adhesion, and homing to medullary and extramedullary sites. RUNX2 enabled these energy-demanding processes by increasing metabolic activity in T-ALL cells through positive regulation of both glycolysis and oxidative phosphorylation. Concurrently, RUNX2 upregulation increased mitochondrial dynamics and biogenesis in T-ALL cells. Finally, as a proof of concept, we demonstrate that immature and KMT2A-R T-ALL cells were vulnerable to pharmacological targeting of the interaction between RUNX2 and its cofactor CBFβ. In conclusion, we show that RUNX2 acts as a dependency factor in high-risk subtypes of human T-ALL through concomitant regulation of tumor metabolism and leukemic cell migration.

Entities:  

Keywords:  Cell migration/adhesion; Leukemias; Molecular biology; Oncology

Year:  2021        PMID: 33555272      PMCID: PMC7954605          DOI: 10.1172/JCI141566

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  103 in total

1.  A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc.

Authors:  F Vaillant; K Blyth; A Terry; M Bell; E R Cameron; J Neil; M Stewart
Journal:  Oncogene       Date:  1999-11-25       Impact factor: 9.867

2.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

3.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

Authors:  Aldo M Roccaro; Yuji Mishima; Antonio Sacco; Michele Moschetta; Yu-Tzu Tai; Jiantao Shi; Yong Zhang; Michaela R Reagan; Daisy Huynh; Yawara Kawano; Ilyas Sahin; Marco Chiarini; Salomon Manier; Michele Cea; Yosra Aljawai; Siobhan Glavey; Elizabeth Morgan; Chin Pan; Franziska Michor; Pina Cardarelli; Michelle Kuhne; Irene M Ghobrial
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

4.  AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.

Authors:  Brandon Faubert; Gino Boily; Said Izreig; Takla Griss; Bozena Samborska; Zhifeng Dong; Fanny Dupuy; Christopher Chambers; Benjamin J Fuerth; Benoit Viollet; Orval A Mamer; Daina Avizonis; Ralph J DeBerardinis; Peter M Siegel; Russell G Jones
Journal:  Cell Metab       Date:  2012-12-27       Impact factor: 27.287

5.  Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.

Authors:  P Ducy; R Zhang; V Geoffroy; A L Ridall; G Karsenty
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

6.  Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.

Authors:  F Otto; A P Thornell; T Crompton; A Denzel; K C Gilmour; I R Rosewell; G W Stamp; R S Beddington; S Mundlos; B R Olsen; P B Selby; M J Owen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

7.  Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene.

Authors:  M Stewart; A Terry; M Hu; M O'Hara; K Blyth; E Baxter; E Cameron; D E Onions; J C Neil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

8.  KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.

Authors:  Jess F Peterson; Linda B Baughn; Kathryn E Pearce; Cynthia M Williamson; Jonna C Benevides Demasi; Renee M Olson; Tony A Goble; Reid G Meyer; Patricia T Greipp; Rhett P Ketterling
Journal:  Genes Chromosomes Cancer       Date:  2018-09-10       Impact factor: 5.006

Review 9.  Paxillin: a crossroad in pathological cell migration.

Authors:  Ana María López-Colomé; Irene Lee-Rivera; Regina Benavides-Hidalgo; Edith López
Journal:  J Hematol Oncol       Date:  2017-02-18       Impact factor: 17.388

10.  Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL.

Authors:  Huining Kang; Nitesh D Sharma; Christian K Nickl; Meenakshi Devidas; Mignon L Loh; Stephen P Hunger; Kimberly P Dunsmore; Stuart S Winter; Ksenia Matlawska-Wasowska
Journal:  Biomark Res       Date:  2018-08-23
View more
  3 in total

1.  The transcription factor RUNX2 drives the generation of human NK cells and promotes tissue residency.

Authors:  Sigrid Wahlen; Filip Matthijssens; Wouter Van Loocke; Sylvie Taveirne; Laura Kiekens; Eva Persyn; Els Van Ammel; Zenzi De Vos; Stijn De Munter; Patrick Matthys; Filip Van Nieuwerburgh; Tom Taghon; Bart Vandekerckhove; Pieter Van Vlierberghe; Georges Leclercq
Journal:  Elife       Date:  2022-07-06       Impact factor: 8.713

Review 2.  Targeting chemokines for acute lymphoblastic leukemia therapy.

Authors:  Zixi Hong; Zimeng Wei; Tian Xie; Lin Fu; Jiaxing Sun; Fuling Zhou; Muhammad Jamal; Qiuping Zhang; Liang Shao
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

Review 3.  Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche.

Authors:  Nitesh D Sharma; Esra'a Keewan; Ksenia Matlawska-Wasowska
Journal:  Front Cell Dev Biol       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.